Katherine Johansen Taber

1.6k total citations
31 papers, 1.1k citations indexed

About

Katherine Johansen Taber is a scholar working on Genetics, Pediatrics, Perinatology and Child Health and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Katherine Johansen Taber has authored 31 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Genetics, 9 papers in Pediatrics, Perinatology and Child Health and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Katherine Johansen Taber's work include BRCA gene mutations in cancer (9 papers), Prenatal Screening and Diagnostics (8 papers) and Cystic Fibrosis Research Advances (8 papers). Katherine Johansen Taber is often cited by papers focused on BRCA gene mutations in cancer (9 papers), Prenatal Screening and Diagnostics (8 papers) and Cystic Fibrosis Research Advances (8 papers). Katherine Johansen Taber collaborates with scholars based in United States, Germany and Belgium. Katherine Johansen Taber's co-authors include Barry D. Dickinson, Dale Muzzey, Modena Wilson, Kyle A. Beauchamp, Robert S. Epstein, Felix W. Frueh, R Verbrugge, Eric J. Stanek, Christopher Sanders and Barnabie Agatep and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Katherine Johansen Taber

29 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katherine Johansen Taber United States 14 481 328 314 233 173 31 1.1k
Peter J. Hulick United States 16 375 0.8× 181 0.6× 227 0.7× 137 0.6× 121 0.7× 46 852
Tessel Rigter Netherlands 14 276 0.6× 184 0.6× 57 0.2× 101 0.4× 89 0.5× 34 646
Mart Kals Estonia 23 365 0.8× 83 0.3× 100 0.3× 72 0.3× 79 0.5× 55 1.2k
Mindy Clyne United States 17 526 1.1× 59 0.2× 43 0.1× 144 0.6× 52 0.3× 26 1.2k
Aimée Paulussen Netherlands 25 553 1.1× 478 1.5× 73 0.2× 212 0.9× 162 0.9× 65 1.9k
Raymond Ng Singapore 22 209 0.4× 93 0.3× 120 0.4× 72 0.3× 599 3.5× 56 1.5k
Katherine Kolor United States 16 508 1.1× 91 0.3× 43 0.1× 207 0.9× 20 0.1× 28 957
Joon‐Ho Yu United States 18 699 1.5× 114 0.3× 31 0.1× 349 1.5× 34 0.2× 38 1.1k
Boleslav Goldman Israel 17 176 0.4× 376 1.1× 105 0.3× 282 1.2× 76 0.4× 28 1.1k
David J. Hunter United States 11 270 0.6× 171 0.5× 37 0.1× 284 1.2× 77 0.4× 14 1.4k

Countries citing papers authored by Katherine Johansen Taber

Since Specialization
Citations

This map shows the geographic impact of Katherine Johansen Taber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katherine Johansen Taber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katherine Johansen Taber more than expected).

Fields of papers citing papers by Katherine Johansen Taber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katherine Johansen Taber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katherine Johansen Taber. The network helps show where Katherine Johansen Taber may publish in the future.

Co-authorship network of co-authors of Katherine Johansen Taber

This figure shows the co-authorship network connecting the top 25 collaborators of Katherine Johansen Taber. A scholar is included among the top collaborators of Katherine Johansen Taber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katherine Johansen Taber. Katherine Johansen Taber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tredici, Andria L. Del, Holly L. Johnson, Alexander Gutin, et al.. (2025). Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder. Journal of Clinical Psychopharmacology. 45(4). 320–328. 1 indexed citations
2.
3.
4.
Goldberg, Judith D., et al.. (2023). Expanded carrier screening: What conditions should we screen for?. Prenatal Diagnosis. 43(4). 496–505. 15 indexed citations
5.
Pierce, Kerry A., Elizabeth L. Tung, Katherine Johansen Taber, et al.. (2023). Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. SHILAP Revista de lepidopterología. 10. 100213–100213. 4 indexed citations
6.
Torres, Raúl, et al.. (2021). Evaluating the efficacy of three carrier screening workflows designed to identify at‐risk carrier couples. Prenatal Diagnosis. 41(7). 896–904. 12 indexed citations
7.
Taber, Katherine Johansen, Rotem Ben‐Shachar, Raúl Torres, et al.. (2021). A guidelines-consistent carrier screening panel that supports equity across diverse populations. Genetics in Medicine. 24(1). 201–213. 19 indexed citations
8.
Ben‐Shachar, Rotem, et al.. (2019). Technology-Driven Noninvasive Prenatal Screening Results Disclosure and Management. Telemedicine Journal and e-Health. 26(1). 8–17. 8 indexed citations
9.
Taber, Katherine Johansen, et al.. (2019). Fragile X syndrome carrier screening accompanied by genetic consultation has clinical utility in populations beyond those recommended by guidelines. Molecular Genetics & Genomic Medicine. 7(12). e1024–e1024. 12 indexed citations
10.
Taber, Katherine Johansen, et al.. (2019). Validation of a digital identification tool for individuals at risk for hereditary cancer syndromes. Hereditary Cancer in Clinical Practice. 17(1). 2–2. 4 indexed citations
11.
Beauchamp, Kyle A., Katherine Johansen Taber, Peter Grauman, et al.. (2019). Sequencing as a first-line methodology for cystic fibrosis carrier screening. Genetics in Medicine. 21(11). 2569–2576. 26 indexed citations
12.
Ready, Kaylene, Katherine Johansen Taber, Natasha Bonhomme, & J. Leonard Lichtenfeld. (2019). Strategies for Improving Access to Hereditary Cancer Testing: Recommendations from Stakeholders. Genetics in Medicine. 21(8). 1702–1704. 4 indexed citations
13.
Beauchamp, Kyle A., Katherine Johansen Taber, & Dale Muzzey. (2019). Clinical impact and cost-effectiveness of a 176-condition expanded carrier screen. Genetics in Medicine. 21(9). 1948–1957. 56 indexed citations
14.
Taber, Katherine Johansen, et al.. (2018). Clinical utility of expanded carrier screening: results-guided actionability and outcomes. Genetics in Medicine. 21(5). 1041–1048. 79 indexed citations
15.
Taber, Katherine Johansen & Barry D. Dickinson. (2014). Pharmacogenomic knowledge gaps and educational resource needs among physicians in selected specialties. Pharmacogenomics and Personalized Medicine. 7. 145–145. 108 indexed citations
16.
Klitzman, Robert, Wendy K. Chung, Karen Marder, et al.. (2014). Psychiatrists’ Views of the Genetic Bases of Mental Disorders and Behavioral Traits and Their Use of Genetic Tests. The Journal of Nervous and Mental Disease. 202(7). 530–538. 14 indexed citations
17.
Taber, Katherine Johansen, Barry D. Dickinson, & Modena Wilson. (2013). The Promise and Challenges of Next-Generation Genome Sequencing for Clinical Care. JAMA Internal Medicine. 174(2). 275–275. 115 indexed citations
18.
Appelbaum, Paul S., Ruth Ottman, Wendy K. Chung, et al.. (2013). Use of Genetic Tests among Neurologists and Psychiatrists: Knowledge, Attitudes, Behaviors, and Needs for Training. Journal of Genetic Counseling. 23(2). 156–163. 88 indexed citations
19.
Stanek, Eric J., Christopher Sanders, Katherine Johansen Taber, et al.. (2012). Adoption of Pharmacogenomic Testing by US Physicians: Results of a Nationwide Survey. Clinical Pharmacology & Therapeutics. 91(3). 450–458. 319 indexed citations
20.
Stein, Mark N., Alan Tan, Katherine Johansen Taber, et al.. (2007). Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in patients with solid tumors. Journal of Clinical Oncology. 25(18_suppl). 2548–2548. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Peter J. Hulick Breakdown of academic impact, for papers by Tessel Rigter Breakdown of academic impact, for papers by Mart Kals Breakdown of academic impact, for papers by Mindy Clyne Breakdown of academic impact, for papers by Aimée Paulussen Breakdown of academic impact, for papers by Raymond Ng Breakdown of academic impact, for papers by Katherine Kolor Breakdown of academic impact, for papers by Joon‐Ho Yu Breakdown of academic impact, for papers by Boleslav Goldman Breakdown of academic impact, for papers by David J. Hunter
Rankless by CCL
2026